Robert E. Waltermire - 16 Jan 2023 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Reporting relationship: Senior VP, Chief Pharma Dev.
Issuer ticker: MDGL
Reported as of: 16 Jan 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 18 Jan 2023, 19:00:26 UTC
Prior SEC filing: 24 Feb 2022
Next SEC filing: 02 Mar 2023
Source filing: View source filing
Reporting owner signature: /s/ Brian J. Lynch**

Key filing fact

Robert E. Waltermire filed Form 4 for MADRIGAL PHARMACEUTICALS, INC. (MDGL) on 18 Jan 2023.

Key facts

This page summarizes Robert E. Waltermire's Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. (MDGL).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 18 Jan 2023, 19:00.

Change

Previous filing in this sequence was filed on 24 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDGL transaction

Common Stock

Award

Transaction value: $0
Shares: +5,667
Change %
Price: $0.000000
Shares after: 5,667
Date: 16 Jan 2023
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 13, 2024, January 13, 2025, January 13, 2026 and January 13, 2027, provided the Reporting Person continues in service with the Issuer on each such date.

SEC remarks

**As attorney-in-fact for Reporting Person